Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(12):1667–1669. doi: 10.1038/bjc.1997.615

Preliminary results of the use of intraperitoneal carbon-adsorbed mitomycin C in intra-abdominal malignancy.

S S Ubhi 1, P McCulloch 1, P S Veitch 1
PMCID: PMC2228208  PMID: 9413960

Abstract

Eleven patients suffering from intra-abdominal malignancy were treated with various doses of intraperitoneal mitomycin C adsorbed onto activated carbon particles. Seven of the patients underwent resection of their primary gastric tumour and all developed potentially life-threatening severe complications that proved to be fatal in four patients. The pattern of complications seen in these patients was unusual in patients undergoing gastrectomy and must be presumed to be secondary to the intraperitoneal mitomycin C. Intraperitoneal mitomycin C at a dose of 25 mg and 50 mg in the presence of an anastomosis or other suture line does not appear to be safe.

Full text

PDF
1667

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bleiberg H., Gerard B., Deguiral P. Adjuvant therapy in resectable gastric cancer. Br J Cancer. 1992 Dec;66(6):987–991. doi: 10.1038/bjc.1992.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cunliffe W. J., Sugarbaker P. H. Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg. 1989 Oct;76(10):1082–1090. doi: 10.1002/bjs.1800761030. [DOI] [PubMed] [Google Scholar]
  3. Faivre J., Justrabo E., Hillon P., Milan C., Klepping C. Gastric carcinoma in Côte d'Or (France). A population-based study. Gastroenterology. 1985 Jun;88(6):1874–1879. doi: 10.1016/0016-5085(85)90013-7. [DOI] [PubMed] [Google Scholar]
  4. Gunderson L. L., Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982 Jan;8(1):1–11. doi: 10.1016/0360-3016(82)90377-7. [DOI] [PubMed] [Google Scholar]
  5. Hagiwara A., Takahashi T., Kojima O., Sawai K., Yamaguchi T., Yamane T., Taniguchi H., Kitamura K., Noguchi A., Seiki K. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet. 1992 Mar 14;339(8794):629–631. doi: 10.1016/0140-6736(92)90792-2. [DOI] [PubMed] [Google Scholar]
  6. Landry J., Tepper J. E., Wood W. C., Moulton E. O., Koerner F., Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1357–1362. doi: 10.1016/0360-3016(90)90344-j. [DOI] [PubMed] [Google Scholar]
  7. Markman M. Intraperitoneal chemotherapy. Semin Oncol. 1991 Jun;18(3):248–254. [PubMed] [Google Scholar]
  8. Siewert J. R., Böttcher K., Roder J. D., Busch R., Hermanek P., Meyer H. J. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg. 1993 Aug;80(8):1015–1018. doi: 10.1002/bjs.1800800829. [DOI] [PubMed] [Google Scholar]
  9. Takahashi T., Hagiwara A., Shimotsuma M., Sawai K., Yamaguchi T. Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J Surg. 1995 Jul-Aug;19(4):565–569. doi: 10.1007/BF00294724. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES